Search research articles
Contact Us
Filters
Showing results (181-190 of 271) with videos related to
Page
of 28
Sort By:
Lancet (London, England)
|
July 14, 2023
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
Jürgen C Becker, Selma Ugurel, Ulrike Leiter, et al.
Oncoimmunology
|
January 27, 2017
Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma
Isabel Poschke, Marta Faryna, Frank Bergmann, et al.
Journal of Cancer Research and Clinical Oncology
|
May 14, 2024
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective
Katharina C Kähler, Ralf Gutzmer, Yenny Angela, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 2, 2024
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade
Eleftheria Chorti, Bernd Kowall, Jessica C Hassel, et al.
Journal of Cancer Research and Clinical Oncology
|
July 5, 2023
Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)
Katharina C Kähler, S Hüning, D Nashan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2025
Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy
S Dugas-Breit, A Forschner, M Erdmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition
Max Schlaak, Carolina Cimminiello, Jacopo Pigozzo, et al.
Cancer Immunology, Immunotherapy : CII
|
February 27, 2019
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis
Bastian Schilling, Alexander Martens, Marnix H Geukes Foppen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin, David Minor, Sandra D'Angelo, et al.
Scientific Reports
|
February 9, 2020
"UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
Nicola Mitwasi, Anja Feldmann, Claudia Arndt, et al.
Page
of 28
Search research articles
Search
Showing results (181-190 of 271) with videos related to
Sort By:
Page
of 28
Lancet (London, England)
|
July 14, 2023
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
Jürgen C Becker, Selma Ugurel, Ulrike Leiter, et al.
Oncoimmunology
|
January 27, 2017
Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma
Isabel Poschke, Marta Faryna, Frank Bergmann, et al.
Journal of Cancer Research and Clinical Oncology
|
May 14, 2024
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective
Katharina C Kähler, Ralf Gutzmer, Yenny Angela, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 2, 2024
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade
Eleftheria Chorti, Bernd Kowall, Jessica C Hassel, et al.
Journal of Cancer Research and Clinical Oncology
|
July 5, 2023
Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)
Katharina C Kähler, S Hüning, D Nashan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2025
Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy
S Dugas-Breit, A Forschner, M Erdmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition
Max Schlaak, Carolina Cimminiello, Jacopo Pigozzo, et al.
Cancer Immunology, Immunotherapy : CII
|
February 27, 2019
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis
Bastian Schilling, Alexander Martens, Marnix H Geukes Foppen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin, David Minor, Sandra D'Angelo, et al.
Scientific Reports
|
February 9, 2020
"UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
Nicola Mitwasi, Anja Feldmann, Claudia Arndt, et al.
Page
of 28